Analyst firms · Oppenheimer · SPRB

Oppenheimer SPRB price target and rating history

Spruce Biosciences Inc. (SPRB) · Health Care

Oppenheimer rates Spruce Biosciences Inc. (SPRB) Outperform with a $283 price target, as of its latest action on Dec 23, 2025. It has published 3 rating actions on SPRB since December 2021, including 0 upgrades and 1 downgrade. Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Oppenheimer's $283 is 83% above that.

Current rating

Outperform

Price target

$283

Median target, all firms

$154.50

Actions on SPRB

3

Oppenheimer price target on SPRB

Every Oppenheimer rating on SPRB

• Dec 23, 2025
  InitiateOppenheimer starts coverage at Outperform, price target $283
• Dec 11, 2024
  DowngradeOppenheimer downgrades to Perform from Outperform
• Dec 17, 2021
  InitiateOppenheimer starts coverage at Outperform, price target $15

How other firms rate SPRB

Each firm's latest rating and stated target in the last 12 months.

Questions about Oppenheimer and SPRB

What is Oppenheimer's price target for SPRB?

Oppenheimer's latest stated price target for Spruce Biosciences Inc. (SPRB) is $283, from its action on Dec 23, 2025.

What is Oppenheimer's rating on SPRB?

Oppenheimer rates SPRB Outperform, a bullish rating, as of Dec 23, 2025.

When did Oppenheimer last change its view on SPRB?

On Dec 23, 2025, Oppenheimer starts coverage at Outperform, price target $283.

How does Oppenheimer's SPRB target compare with other analysts?

Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Oppenheimer's $283 is 83% above that.

More SPRB rating histories

• Guggenheim3
• Leerink Partners4
• H.C. Wainwright3

All Oppenheimer ratingsSPRB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.